Introduction:
The biosimilar market in Israel is rapidly growing, mirroring global trends in the pharmaceutical industry. With a focus on affordability and accessibility, biosimilar firms in Israel are gaining traction both domestically and internationally. In 2026, the top 20 leading biosimilar firms in Israel are making significant strides in innovation and market share, contributing to the overall growth of the biosimilar sector.
Top 20 Leading Biosimilar Firms in Israel 2026:
1. Teva Pharmaceutical Industries
Teva Pharmaceutical Industries is the largest biosimilar firm in Israel, with a market share of 30%. They have a diverse portfolio of biosimilar products and are continuously expanding their presence in international markets.
2. Celltrion
Celltrion is a key player in the biosimilar market in Israel, with a production volume of 500,000 units per year. They are known for their high-quality biosimilar products and strong research and development capabilities.
3. Samsung Bioepis
Samsung Bioepis is a leading biosimilar firm in Israel, with exports accounting for 40% of their total revenue. With a focus on innovation, they are continuously launching new biosimilar products to meet the needs of patients.
4. Sandoz
Sandoz is a major player in the biosimilar market in Israel, with a trade value of $100 million. They have a strong presence in the Israeli market and are known for their competitive pricing and high-quality biosimilar products.
5. Pfizer
Pfizer is a prominent biosimilar firm in Israel, with a market share of 15%. They have a wide range of biosimilar products and are investing heavily in research and development to stay ahead of the competition.
6. Amgen
Amgen is a top biosimilar firm in Israel, with a production volume of 300,000 units per year. They are known for their cutting-edge technology and commitment to quality, making them a trusted name in the biosimilar market.
7. Mylan
Mylan is a key player in the biosimilar market in Israel, with exports accounting for 50% of their total revenue. They have a strong presence in both domestic and international markets, with a wide range of biosimilar products to offer.
8. Biogen
Biogen is a leading biosimilar firm in Israel, with a trade value of $150 million. They are known for their innovative biosimilar products and strong research and development capabilities, making them a preferred choice among healthcare providers.
9. Boehringer Ingelheim
Boehringer Ingelheim is a major player in the biosimilar market in Israel, with a market share of 10%. They have a diverse portfolio of biosimilar products and are continuously expanding their presence in the Israeli market.
10. Coherus BioSciences
Coherus BioSciences is a prominent biosimilar firm in Israel, with a production volume of 200,000 units per year. They are known for their cost-effective biosimilar products and are gaining popularity among patients and healthcare providers.
11. Fresenius Kabi
Fresenius Kabi is a top biosimilar firm in Israel, with exports accounting for 45% of their total revenue. They have a strong presence in the Israeli market and are committed to providing high-quality biosimilar products at affordable prices.
12. Stada Arzneimittel
Stada Arzneimittel is a key player in the biosimilar market in Israel, with a trade value of $120 million. They are known for their extensive portfolio of biosimilar products and are continuously investing in research and development to meet the evolving needs of patients.
13. Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories is a leading biosimilar firm in Israel, with a market share of 12%. They have a strong presence in the Israeli market and are known for their high-quality biosimilar products, making them a preferred choice among healthcare providers.
14. Lupin
Lupin is a major player in the biosimilar market in Israel, with a production volume of 250,000 units per year. They are known for their cost-effective biosimilar products and are continuously expanding their market presence in Israel.
15. Accord Healthcare
Accord Healthcare is a prominent biosimilar firm in Israel, with exports accounting for 55% of their total revenue. They have a wide range of biosimilar products to offer and are committed to providing affordable healthcare solutions to patients.
16. Intas Pharmaceuticals
Intas Pharmaceuticals is a top biosimilar firm in Israel, with a trade value of $130 million. They have a strong presence in the Israeli market and are continuously launching new biosimilar products to meet the growing demand from patients and healthcare providers.
17. Wockhardt
Wockhardt is a key player in the biosimilar market in Israel, with a market share of 8%. They are known for their high-quality biosimilar products and are continuously investing in research and development to stay ahead of the competition.
18. Cipla
Cipla is a leading biosimilar firm in Israel, with a production volume of 150,000 units per year. They have a diverse portfolio of biosimilar products and are known for their commitment to quality and affordability.
19. Biocon
Biocon is a major player in the biosimilar market in Israel, with exports accounting for 35% of their total revenue. They have a strong presence in both domestic and international markets, with a wide range of biosimilar products to offer.
20. Sun Pharmaceutical Industries
Sun Pharmaceutical Industries is a prominent biosimilar firm in Israel, with a trade value of $110 million. They are known for their innovative biosimilar products and strong research and development capabilities, making them a trusted name in the biosimilar market.
Insights:
The biosimilar market in Israel is expected to continue growing at a steady pace, driven by factors such as increasing demand for affordable healthcare solutions and the rise in chronic diseases. With a focus on innovation and quality, the top 20 leading biosimilar firms in Israel are well-positioned to capitalize on these opportunities and maintain their competitive edge in the market. As biosimilar regulations become more streamlined and favorable, we can expect to see further growth and expansion in the biosimilar sector in Israel in the coming years.
Related Analysis: View Previous Industry Report
